In the study of the mechanism of basement membrane turnover in malignant CRC progression, Spaderna et al. [44] proposed that the progression of basement membrane loss and the differentiation of epithelial cell phenotype upon ZEB1 knockdown is similar to MET, and targeting relevant EMT-related transcriptional repressors in ZEB1 or other tumors may be a choice with therapeutic potential to prevent malignant metastatic progression. The gene discussed is ZEB1; the disease is colorectal carcinoma.